Literature DB >> 11564660

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.

M van Heek1, C Farley, D S Compton, L Hoos, H R Davis.   

Abstract

1. Ezetimibe potently inhibits the transport of cholesterol across the intestinal wall, thereby reducing plasma cholesterol in preclinical animal models of hypercholesterolemia. The effect of ezetimibe on known absorptive processes was determined in the present studies. 2. Experiments were conducted in the hamster and/or rat to determine whether ezetimibe would affect the absorption of molecules other than free cholesterol, namely cholesteryl ester, triglyceride, ethinylestradiol, progesterone, vitamins A and D, and taurocholic acid. In addition, to determine whether exocrine pancreatic function is involved in the mechanism of action of ezetimibe, a biliary anastomosis model, which eliminates exocrine pancreatic function from the intestine while maintaining bile flow, was established in the rat. 3. Ezetimibe reduced plasma cholesterol and hepatic cholesterol accumulation in cholesterol-fed hamsters with an ED(50) of 0.04 mg kg(-1). Utilizing cholesteryl esters labelled on either the cholesterol or the fatty acid moiety, we demonstrated that ezetimibe did not affect cholesteryl ester hydrolysis and the absorption of fatty acid thus generated in both hamsters and rats. The free cholesterol from this hydrolysis, however, was not absorbed (92 - 96% inhibition) in the presence of ezetimibe. Eliminating pancreatic function in rats abolished hydrolysis of cholesteryl esters, but did not affect the ability of ezetimibe to block absorption of free cholesterol (-94%). Ezetimibe did not affect the absorption of triglyceride, ethinylestradiol, progesterone, vitamins A and D, and taurocholic acid in rats. 4. Ezetimibe is a potent inhibitor of intestinal free cholesterol absorption that does not require exocrine pancreatic function for activity. Ezetimibe does not affect the absorption of triglyceride as a pancreatic lipase inhibitor (Orlistat) would, nor does it affect the absorption of vitamin A, D or taurocholate, as a bile acid sequestrant (cholestyramine) would.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564660      PMCID: PMC1572957          DOI: 10.1038/sj.bjp.0704260

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

Review 1.  Postprandial lipoprotein metabolism and atherosclerosis.

Authors:  F Karpe
Journal:  J Intern Med       Date:  1999-10       Impact factor: 8.989

2.  The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys.

Authors:  M van Heek; D S Compton; H R Davis
Journal:  Eur J Pharmacol       Date:  2001-03-09       Impact factor: 4.432

3.  Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.

Authors:  M van Heek; T M Austin; C Farley; J A Cook; G G Tetzloff; H R Davis
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

Review 4.  Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk.

Authors:  E Ros
Journal:  Atherosclerosis       Date:  2000-08       Impact factor: 5.162

5.  Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits.

Authors:  J Higaki; S Hara; N Takasu; K Tonda; K Miyata; T Shike; K Nagata; T Mizui
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-08       Impact factor: 8.311

6.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

Review 7.  Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins.

Authors:  D B Zilversmit
Journal:  Clin Chem       Date:  1995-01       Impact factor: 8.327

8.  The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine.

Authors:  R E Burrier; A A Smith; D G McGregor; L M Hoos; D L Zilli; H R Davis
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

9.  The effect of pancreatic diversion on lymphatic absorption and esterification of cholesterol in the rat.

Authors:  S M Watt; W J Simmonds
Journal:  J Lipid Res       Date:  1981-01       Impact factor: 5.922

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  34 in total

1.  Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability.

Authors:  Bilal S Abuasal; Courtney Lucas; Breanne Peyton; Alaadin Alayoubi; Sami Nazzal; Paul W Sylvester; Amal Kaddoumi
Journal:  Lipids       Date:  2012-01-24       Impact factor: 1.880

Review 2.  Management strategies of dyslipidemia in the elderly: 2005.

Authors:  Tarek Helmy; Amar D Patel; Fadi Alameddine; Nanette K Wenger
Journal:  MedGenMed       Date:  2005-10-10

Review 3.  New insights into the molecular mechanism of intestinal fatty acid absorption.

Authors:  Tony Y Wang; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-09-18       Impact factor: 4.686

Review 4.  Protein mediators of sterol transport across intestinal brush border membrane.

Authors:  J Mark Brown; Liqing Yu
Journal:  Subcell Biochem       Date:  2010

Review 5.  Mechanisms involved in the intestinal absorption of dietary vitamin A and provitamin A carotenoids.

Authors:  Earl H Harrison
Journal:  Biochim Biophys Acta       Date:  2011-06-12

6.  Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model.

Authors:  Doo Sun Sim; Myung Ho Jeong; Dae Sung Park; Jung Ha Kim; Kyung Seob Lim; Hyun Kuk Kim; Sung Soo Kim; Jae Yeong Cho; Hae Chang Jeong; Keun Ho Park; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park
Journal:  Korean Circ J       Date:  2015-03-24       Impact factor: 3.243

7.  Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.

Authors:  Tomás Zambrano; Nicolás Saavedra; Fernando Lanas; José Caamaño; Luis A Salazar
Journal:  Mol Diagn Ther       Date:  2015-02       Impact factor: 4.074

Review 8.  Newer pharmaceutical agents to treat lipid disorders.

Authors:  Michael H Davidson
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 9.  Role of selective cholesterol absorption inhibition in the management of dyslipidemia.

Authors:  Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

10.  Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats.

Authors:  Margaret van Heek; Constance Farley; Douglas S Compton; Lizbeth M Hoos; April Smith-Torhan; Harry R Davis
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.